At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 351–360 of 615 results.
-
There is not an accepted or usual approach to treat patients 75 years of age or older diagnosed with diffuse large B-cell lymphoma (DLBCL). Doctors are seeking effective but less intensive treatment regimens, with fewer side effects, for these patients. A standard treatment for DLBCL is R-CHOP (a combination of the drugs rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
-
In addition, their cancers have a mutation (change) in the G12C location of the KRAS gene. Olomorasib may help slow or stop the growth of cancers with KRAS G12C mutations. It is taken orally (by mouth).
-
Germ cell tumors (GCTs) include ovarian teratomas and testicular cancers. The standard treatment for "low-risk" GCTs includes complete removal by surgery followed by chemotherapy with cisplatin, bleomycin, and etoposide, unless the patient is a young child, in which case careful observation may be adequate. GCTs are considered "standard risk" if the patient is under age 25 at diagnosis, the tumor was not completely removed during surgery or has spread to other parts of the body, or proteins in the blood called tumor markers are elevated. The standard treatment for standard-risk GCTs includes chemotherapy with cisplatin, bleomycin, and etoposide followed by surgery, followed by more chemotherapy if needed.
-
Researchers want to find the best dose of xaluritamig to treat prostate cancer. The people in this study have prostate cancer that has not metastasized (spread) but keeps growing after treatment. Their doctors believe their cancers may respond to hormonal therapies that lower cancer-fueling testosterone. This type of cancer is called non-metastatic castration-sensitive prostate cancer.
-
After people receive chemotherapy for colon cancer, doctors may be able to detect tumor DNA in the blood ("circulating tumor DNA" or ctDNA). If there is ctDNA in the blood, a patient's cancer may be more likely to come back. It is standard for people with ctDNA in their blood to be monitored ("active surveillance"), but investigators would like to know if immediate treatment of these patients can prevent cancer recurrence.
-
Radiation delivered to metastatic tumors is known to cause damage to the DNA (genetic information) in the cancer cells, which causes them to die. An ATM mutation reduces cancer cells' ability to fix damage to their DNA, making it more likely that the radiation will kill ATM-mutated cancer cells. Lower doses of radiation therapy may cause fewer side effects than standard doses. In this study, researchers will observe the side effects of reduced-dose radiation therapy in patients with metastatic tumors that contain an ATM mutation and the rate at which tumors grow back (recur) after this treatment. It is hoped that lowering the radiation dose will be effective while reducing the side effects of treatment.
-
Radical hysterectomy via laparotomy (open surgery) is the standard surgical approach for people with early-stage cervical cancer. A radical hysterectomy involves removal of the uterus, cervix, parametria (tissue beside the cervix), and upper part of the vagina; the ovaries, fallopian tubes, and nearby lymph nodes may also be removed. With laparotomy, the operation is performed through a large incision in the abdomen.
-
The purpose of this study is to assess the safety and effectiveness of the drug trastuzumab deruxtecan (also known as DS-8201A) in patients with inoperable or metastatic solid tumors that produce too much of a protein called HER2, including biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers.
-
The genetic and biochemical makeup of a tumor influences its aggressiveness and the choice of the most appropriate therapy. The purpose of this research study is to determine the genetic and biochemical makeup of neuroblastic tumors, including neuroblastoma, ganglioneuroblastoma, ganglioneuroma, and paraganglioma. These research studies will include analysis of substances called markers that exist on the surface of cancer cells; cytogenetic studies; the identification of genes related to the development of these cancers and to tumor growth; and studies of tumor growth in test tubes. Patients' blood and bone marrow will also be tested for the presence of tumor cells or leukemia cells.
-
Casdozokitug blocks an immune system protein called IL-27. By binding to and blocking IL-27, casdozokitug may help immune cells fight cancer. Toripalimab also helps the immune system fight cancer. Bevacizumab prevents the growth of new blood vessels that feed the cancer. All three drugs are given intravenously (by vein).